OSLO, Norway, April 23, 2018 /PRNewswire/ --
The Board of Directors of Nordic Nanovector ASA ("Nordic Nanovector"or the "Company") has on 23 April 2018 resolved to grant 15 000 Performance Share Units ("PSUs") to new employees under the Company's new equity incentive plan that was approved at the Company's extraordinary general meeting
About Nordic Nanovector
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.
Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin's Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.
The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications.
Further information about the Company can be found at www.nordicnanovector.com
This information is subject to a duty of disclosure pursuant to Section 3.2 of the continuing obligations for listed companies.
For further information, please contact:
Malene Brondberg, VP Investor Relations and Corporate Communications
This information was brought to you by Cision http://news.cision.com
View original content:http://www.prnewswire.com/news-releases/nordic-nanovector-asa---issuance-of-psus-300634583.html
SOURCE Nordic Nanovector
Subscribe to our Free Newsletters!